Services within 3D imaging

Quantitative 3D imaging using light sheet fluorescent microscopy is currently revolutionizing
the way we look at pre-clinical endpoints and biodistribution

Whole organ immunolabeling

  • C-Fos signatures of drug treatment or physiological conditions (CNS)
  • Quantification of TH neurons in models of PD (CNS)
  • Quantification of plaques in models of AD (CNS)
  • Gene therapy readouts such as GFP, RFP, Luciferase (CNS)
  • Vascular remodelling (all organs)
  • Beta cell mass in T1 and T2 diabetes
Publications
Movies

In vivo distribution

  • BBB passage of fluorescently labelled molecules (CNS)

  • Antibodies: In vivo distribution of fluorescently labelled antibodies (all organs)

  • Peptides: In vivo distribution of fluorescently labelled peptides (all organs)

  • ASO’s: In vivo distribution of fluorescently labelled ASO’s (all organs)

     

Publications
Movies

Get in touch

Please get in touch if you are interested in discussing how to get started with your study. Reach out to Principal Scientist Jacob Hecksher-Søresensen jhs@gubra.dk Ph. +45 2986 9407

Gubra 3D Experience

To enable fast and efficient data mining of quantitative 3D imaging data, Gubra has developed a web-based 3D imaging data viewer (Gubra 3D Experience, G3DE). This resource provides researchers with a platform for exploring Gubra’s published 3D imaging data in further detail.

Click here to explore individual brain regions of interest, display quantitative c-Fos data and filter for regions with statistically significant response to drug treatment.

Open 3D viewer

3D imaging publications

Quantitative Gubra 3D imaging studies across various organs.

CNS
Kidney
Pancreas
Cardiovascular system

Gubra imaging approach

Gubra is a world leader in whole organ imaging and AI-assisted quantification. We strongly believe that this approach is the future in pre-clinical drug discovery.

Quantitative 3D light sheet microscopy can be applied to all organs in mouse and rat. It can be used in combination with immunolabelling or in vivo distribution of fluorescently labelled molecules.

Our imaging platform is integrated into Gubra’s pipeline and works seamlessly in combination with our animal models to ensure absolute quantification of disease endpoints

 

Related Links:

Main offerings

 

  • Quantitative whole brain imaging
  • Neuronal activation (drug induced or physiological)
  • Whole organ quantification of Islet counts and beta cell volume in model of T1 and T2 diabetes
  • Glomeruli count and volumetric analysis in models of kidney disease
  • Vascular remodelling in heart, eyes and adipose tissue
  • Drug distribution (all organs)
  • Customized endpoints – any specific endpoint you have in mind

Get in touch

Please get in touch if you are interested in discussing how to get your study started.

Jacob Hecksher-Søresensen

Principal Scientist

jhs@gubra.dk
+45 2986 9407

© 2021 Gubra